## Distinguishing MDR-TB from XDR-TB ### Definition Framework **Key Point:** MDR-TB (Multi-Drug Resistant TB) is defined as resistance to **at least isoniazid (INH) AND rifampicin (RIF)** — the two most potent first-line anti-TB drugs. This is the minimum criterion and the feature that **best distinguishes MDR-TB** as a category. **Key Point:** XDR-TB (Extensively Drug-Resistant TB) is defined as MDR-TB **PLUS** resistance to at least one fluoroquinolone AND at least one injectable second-line agent (amikacin, capreomycin, or kanamycin). XDR-TB is a *subset* of MDR-TB with additional resistance. ### Why Option A is Correct The question asks which feature **best distinguishes MDR-TB from XDR-TB** in this patient's profile. The patient has resistance to INH and RIF — this is the **defining, distinguishing criterion of MDR-TB**. Option A ("Resistance to isoniazid and rifampicin alone") correctly identifies the hallmark that places this patient in the MDR-TB category rather than XDR-TB. ### Comparison Table | Feature | MDR-TB | XDR-TB | |---|---|---| | **Resistant to INH + RIF** | Yes (mandatory) | Yes (mandatory) | | **Resistant to ≥1 fluoroquinolone** | No | Yes (mandatory) | | **Resistant to ≥1 injectable agent** | No | Yes (mandatory) | | **Prognosis** | Better with 2nd-line regimen | Poorer; limited options | | **Treatment** | 20 months (WHO 2019) | 20+ months; bedaquiline/linezolid needed | ### Why Other Options Are Incorrect - **Option B:** Describes XDR-TB (MDR + fluoroquinolone + injectable resistance), not MDR-TB. - **Option C:** While it is true that this patient retains susceptibility to fluoroquinolones and injectables, this feature describes what MDR-TB *lacks* compared to XDR-TB — it is not the *defining* feature of MDR-TB itself. The positive definition (INH + RIF resistance) is the best distinguishing criterion. - **Option D:** Resistance to all first- and second-line drugs is not the standard WHO definition of either MDR-TB or XDR-TB; this would represent a pan-resistant or totally drug-resistant (TDR) profile. ### Clinical Pearl **Clinical Pearl:** Per WHO 2022 definitions, MDR-TB = resistance to INH + RIF. XDR-TB = MDR-TB + resistance to any fluoroquinolone + at least one of bedaquiline or linezolid (updated 2021 WHO criteria). The classic injectable-based XDR definition (amikacin/capreomycin) was the pre-2021 standard; both definitions hinge on INH + RIF resistance as the MDR-TB foundation. **High-Yield (Harrison's Principles of Internal Medicine, 21st ed.):** The minimum criterion for MDR-TB is resistance to isoniazid and rifampicin. Any additional resistance to key second-line agents upgrades the classification to XDR-TB.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.